Innovation has recently become a more critical element of progress to meet the needs of the times. Today, research is holistically proposed as "an innovation ecosystem" to realize the maintenance and progress of a nation and its capital markets to deliver sustained economic growth for an improved society. In order to move towards finding solutions to the problems identified for our country, we envisioned our future social needs. With this approach we have deliberately broken down the constraining walls of existing fields and organization, to facilitate collaborative social experiment by the industry-academia-government collaboration. Breaking such legacy thinking we explicitly expect to facilitate the practical use translation from the fundamental research stage. This article describes how we set a vision to promote "open innovation" through the industry-academia-government collaboration. Our progress to date is summarized with three points of view such as i) infrastructure (the framework of regulation, policy or environmental maintenance etc.), ii) investment, iii) human resources development) which are critical to build "an innovation ecosystem".
The history of Ajinomoto Co., Inc. started with the open innovation between Professor Kikunae Ikeda, who discovered umami, and Saburosuke Suzuki II, who commercialized the umami seasoning AJI-NO-MOTO®. Since the founding of Ajinomoto Co., Inc., such open innovation has expanded our business. This article mentions specific examples of our recent open innovation trials and the key factors to our success. Expectations for new open innovation utilizing the Innovation Center of Nanomedicine(iCONM)as the core institute in "Center of Open Innovation Network for Smart Health (COINS)," an initiative under the "Center of Innovation Science and Technology based Radical Innovation and Entrepreneurship Program (COI STREAM)" of the Ministry of Education, Culture, Sports, Science and Technology are also described.
Exosomes are a type of cell-secreted nanovesicles that have received significant attention as promising biomarkers for early detection of intractable diseases such as cancer and for evaluating treatment efficacy. Also, expectations on their therapeutic application such as drug delivery system for nucleic acid-based drugs and regenerative medicine using mesenchymal stem cell-derived exosomes are now rising. However, it is technologically difficult to analyze or identify a heterogeneous population of particles ranging from several tens to one hundred nanometers, and hence, there is a growing demand for a new analytical method of nanoparticles among researchers working on extracellular vesicles. In this article, the authors present an analytical platform for nanoparticles, which allows particle immunoelecrophoresis on a microfluidic chip, that has been invented by them and developed jointly with Nikon, mainly focusing on the background of the development and technological outlines. The developed platform allows detection of individual nanoparticles or nanovesicles of less than 50 nm in diameter and enables the characterization of nanoparticles based on indexes such as concentration, diameter, zeta potential, and surface antigenicity.
To discuss the activities and roles of a bioventure company through the experiences at NanoCarrier Co., Ltd., whose core technology, micellar nanoparticle technology, was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo and Professor Teruo Okano of Tokyo Women's Medical University, and which was established for developing and commercializing DDS drug products for the treatment of cancer utilizing its technology.
Looking back in own history is sometime good to get perspective for the next ten years. Since we found a new polysaccharide/DNA complex in 1999, we have worked on clarifying its fundamental properties and complexation mechanism as well as seeking application as a platform technology in DDS. There were several major stepping stones to lead us to the present. Finding of dectin-1 receptor in antigen presenting cells and targeting delivery of DNA through dectin-1. Human encounters at right time and right place to start our bio-venture company: NapaJen Pharma.
In modern medicine, many numbers and kinds of combination products have increased dramatically. Typical examples of combination products are a drug-eluting stent, a bactiseal catheter, and a photodynamic therapy for cancer treatments. The photodynamic therapy is a minimally invasive, and double targeting therapy that we inject a photosensitizer targeting cancer cells and irradiate a laser around or to the cancer locally. In 2007, we started an investigator-initiated clinical trial of the photodynamic therapy using a Talaporfin and a laser, to expand indication of malignant brain tumors in addition to early lung cancers. In 2013, Ministry of Health, Labour and Welfare has approved the photodynamic therapy for malignant brain tumors. We here describe the experiences of the trial and the future direction about another combination product of a sonodynamic therapy using a drug and a focused high-intensity ultrasound.
[Serial] Fundamentals of statistical analysis in biomedical research